Namieta Janssen, MD
Rheumatology · Sugar Land, TXNPI 1609979947
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $305,280 of the $374,745 with a category attached, or 81.5%. 29 manufacturers reported payments, led by GSK at 45.7% of the total. Reporting peaked in 2019 at $104,078 and has fallen 98.4% since, to $1,715 in 2025. Among rheumatology clinicians in TX with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,141 payments — averaging $328.44 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$171K
- UCB, Inc.$132K
- Lilly USA, LLC$41K
- Aurinia Pharma U.S., Inc.$6K
- AstraZeneca$5K
- Regeneron Healthcare Solutions, Inc.$3K
- plus $16K from 23 others
What the payments were for
- Consulting fees$24,4487%
- Speaking & faculty fees$305,28081%
- Travel & lodging$18,6995%
- Food & beverage$21,6846%
- Education$4,6341%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 165 | $171,167 |
| UCB, Inc. | 318 | $131,623 |
| Lilly USA, LLC | 76 | $41,222 |
| Aurinia Pharma U.S., Inc. | 15 | $6,071 |
| AstraZeneca(2 entities) | 61 | $5,294 |
| Regeneron Healthcare Solutions, Inc. | 12 | $3,417 |
| Amgen(2 entities) | 128 | $3,201 |
| Johnson & Johnson(2 entities) | 45 | $2,912 |
| Sanofi | 35 | $2,899 |
| AbbVie | 97 | $2,218 |
| Novartis | 30 | $1,371 |
| Pfizer | 53 | $905 |
| E.r. Squibb & Sons, L.L.C. | 38 | $735 |
| Radius Health, Inc. | 10 | $351 |
| Genentech USA, Inc. | 11 | $313 |
| Mallinckrodt Enterprises LLC | 6 | $308 |
| Bristol Myers Squibb | 11 | $133 |
| Mallinckrodt Hospital Products Inc. | 5 | $105 |
| Organon | 7 | $78 |
| Sanofi-aventis U.S. LLC | 1 | $75 |
| Sobi, Inc | 2 | $64 |
| Merck | 4 | $61 |
| Medexus Pharma, Inc. | 4 | $60 |
| Antares Pharma, Inc. | 2 | $41 |
| Boehringer Ingelheim | 1 | $33 |
| Fresenius Kabi USA, LLC | 1 | $31 |
| Alvogen Inc | 1 | $24 |
| Teva Pharmaceuticals USA, Inc. | 1 | $18 |
| Ultragenyx Pharmaceutical Inc. | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$374,745 in reported general payments places this provider in the 95th percentile of 512 rheumatology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Humira(Cf) PenAdalimumab | 31 | $233,555 |
| RasuvoMethotrexate/Pf | 13 | $8,768 |
| Hydroxychloroquine Sulfate | 163 | $7,931 |
| MethotrexateMethotrexate Sodium | 249 | $7,768 |
| Mycophenolate Mofetil | 13 | $2,737 |
| Prednisone | 179 | $1,738 |
| Leflunomide | 27 | $1,519 |
| Sulfasalazine | 25 | $1,130 |
| Celecoxib | 36 | $869 |
| Risedronate Sodium | 19 | $858 |
| Gabapentin | 24 | $760 |
| Duloxetine Hcl | 24 | $467 |
| Folic Acid | 19 | $190 |
| Allopurinol | 19 | $114 |
| Tramadol Hcl | 14 | $91 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Medexus Pharma, Inc.Rasuvo | $60 | $8,76813 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 512 rheumatology providers in Texas.
Other rheumatology in Sugar Land
- Jesus HernandezSugar Land$186K
- Susan MathewSugar Land$56K
- John CushDallas$3.7M
- Sanjay ChabraEl Paso$3.3M
- Dhiman BasuColleyville$1.8M
- Frank WellborneNew Braunfels$1.4M
- Christopher ParkerWest Lake Hills$1.4M
- Pendleton WickershamSan Antonio$954K
- Henry TownsendPlano$738K
- Zoran KurepaDallas$483K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.